Sensei Biotherapeutics, Inc.

NasdaqGM:SNSE Stock Report

Market Cap: US$13.4m

Sensei Biotherapeutics Management

Management criteria checks 2/4

Sensei Biotherapeutics' CEO is John Celebi, appointed in Feb 2018, has a tenure of 6.75 years. total yearly compensation is $1.01M, comprised of 52.6% salary and 47.4% bonuses, including company stock and options. directly owns 0.25% of the company’s shares, worth $33.39K. The average tenure of the management team and the board of directors is 1.9 years and 3.8 years respectively.

Key information

John Celebi

Chief executive officer

US$1.0m

Total compensation

CEO salary percentage52.6%
CEO tenure6.8yrs
CEO ownership0.2%
Management average tenure1.9yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

Nov 03
Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

Jul 02
We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Mar 14
Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Aug 14
We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06

Aug 09

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Apr 18
Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans

Nov 16
Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans

CEO Compensation Analysis

How has John Celebi's remuneration changed compared to Sensei Biotherapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$30m

Jun 30 2024n/an/a

-US$30m

Mar 31 2024n/an/a

-US$32m

Dec 31 2023US$1mUS$532k

-US$34m

Sep 30 2023n/an/a

-US$39m

Jun 30 2023n/an/a

-US$45m

Mar 31 2023n/an/a

-US$46m

Dec 31 2022US$2mUS$513k

-US$49m

Sep 30 2022n/an/a

-US$46m

Jun 30 2022n/an/a

-US$42m

Mar 31 2022n/an/a

-US$41m

Dec 31 2021US$7mUS$487k

-US$37m

Sep 30 2021n/an/a

-US$33m

Jun 30 2021n/an/a

-US$28m

Mar 31 2021n/an/a

-US$23m

Dec 31 2020US$2mUS$395k

-US$20m

Compensation vs Market: John's total compensation ($USD1.01M) is above average for companies of similar size in the US market ($USD646.00K).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.

CEO

John Celebi (52 yo)

6.8yrs

Tenure

US$1,012,289

Compensation

Mr. John K. Celebi, MBA serves as President, Chief Executive Officer and Director of Alvaxa Biosciences, Incorporated since February 2018. Mr. Celebi serves as President and Chief Executive Officer of Sens...

Leadership Team

NamePositionTenureCompensationOwnership
John Celebi
President6.8yrsUS$1.01m0.25%
$ 33.4k
Edward Van der Horst
Chief Scientific Officer1.9yrsUS$739.08k0.14%
$ 18.9k
Josiah Craver
Senior VP of Financeless than a yearno datano data
Lora Pike
Vice President of Investor Relations & Communicationsno datano datano data
Christopher Gerry
Senior VP2.3yrsno datano data
Stephanie Krebs
Chief Business Officerless than a yearno datano data
Aaron Weitzman
Chief Medical Officerno datano datano data

1.9yrs

Average Tenure

50yo

Average Age

Experienced Management: SNSE's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
John Celebi
President6.8yrsUS$1.01m0.25%
$ 33.4k
Thomas Ricks
Independent Director8.9yrsUS$75.56k1.35%
$ 181.3k
William Ringo
Independent Chairman2.7yrsUS$101.57k0.063%
$ 8.5k
Robert Holmen
Independent Director7.8yrsUS$73.39k0.084%
$ 11.3k
Richard Ulevitch
Member of Immuno-Oncology Advisory Board3.5yrsno datano data
Deneen Vojta
Independent Director3.8yrsUS$69.32k0.018%
$ 2.4k
James Peyer
Independent Director4.8yrsUS$68.43kno data
Alain Algazi
Member of Immuno-Oncology Advisory Boardno datano datano data
Maura Gillison
Member of Immuno-Oncology Advisory Board3.5yrsno datano data
Kristian Humer
Independent Director3.3yrsUS$62.24k0.018%
$ 2.4k
Sara Pai
Member of Immuno-Oncology Advisory Boardno datano datano data
Robert Schreiber
Member of Immuno-Oncology Advisory Boardno datano datano data

3.8yrs

Average Tenure

60yo

Average Age

Experienced Board: SNSE's board of directors are considered experienced (3.8 years average tenure).